22 transcriptional dysregulations may contribute to the metabolic disorders observed in 45 prenatal BPA-treated female sheep. 46 47
Abstract: 23
Background: Bisphenol-A (BPA) exposure is widespread and early life exposure is 24 associated with metabolic syndrome. While visceral adipose tissue (VAT) and 25 subcutaneous adipose tissue (SAT) are implicated in the development of metabolic 26 syndrome, the adipose depot-specific effects of prenatal BPA treatment are poorly 27 understood. 28
Objective: To determine the impact of prenatal BPA exposure on the transcriptome of 29 VAT and SAT adipose depots. 30
Methods: RNA sequencing was performed on SAT and VAT from 21-month old control 31 and prenatal BPA-treated female sheep. Differences in transcriptional profiling of SAT 32 and VAT in controls and the effect of prenatal BPA treatment on individual genes and 33 gene pathways were determined. 34
Results: There were 179 differentially expressed genes (p adjusted <0.05, log 2 -fold change 35 >2.5) between SAT and VAT. Development and immune response pathways were 36 upregulated in SAT, while metabolic pathways were upregulated in VAT. In SAT, BPA-37 treatment resulted in differential expression of 108 genes (78% upregulated with BPA) 38 and altered pathways (immune response downregulated, RNA processing upregulated). 39
In contrast in VAT, BPA-treatment differentially expressed 4 genes and upregulated 40 chromatin and RNA processing pathways. 41
Conclusion: Prenatal BPA-treatment induces adult depot-specific alterations in RNA 42 expression in inflammation, RNA processing, and chromatin, reflecting the diverse roles 43 of SAT and VAT in regulating lipid storage and insulin sensitivity. These adipose tissue 44 48
Introduction 49
The worldwide prevalence of obesity tripled between 1975 and 2016, until 650 50 million adults were classified as obese and another 1.25 billion adults were overweight 51 (WHO, 2018) . This rapid increase in obesity and associated complications created an 52 annual economic burden due to healthcare costs estimated between $147 and $210 53 billion in the United States (US) alone (Levi et al., 2010; Regnier and Sargis, 2014) . The 54 main risk factors for the development of obesity are genetic predisposition and lifestyle 55 factors, including increased caloric intake and decreased energy expenditure (Williams 56 et al., 2015) . However, these factors alone fail to explain the global rise in obesity 57 prevalence. Accumulating evidence from epidemiological and animal studies 58 demonstrate early development exposures to environmental endocrine disrupting 59 chemicals, such as bisphenol A (BPA), are risk factors for obesity (Zimmet and Alberti, 60 2006; Holtcamp, 2012; Kelishadi et al., 2013; Heindel et al., 2015) . Over 90% of US 61 adults and 96% of pregnant women have detectable urinary concentrations of BPA 62 (Calafat et al., 2008; Woodruff et al., 2011) , indicating widespread exposure and risk 63 particularly during the prenatal period. Used in the production of epoxy and 64 polycarbonate resins, BPA is found in common household plastics. Although its main 65 endocrine disrupting function is its estrogenic activity (Vogel, 2009; Vom Saal, 2016) , 66 BPA is also known for its obesogenic role (Legeay and Faure, 2017) . BPA affects 67 adipose tissue via estrogenic actions as well as disruption of the thyroid receptor and 68 activation of peroxisome proliferator-activated receptor gamma (PPARG) (Vom Saal et 69 al., 2012; Ahmed, 2016; Ahmed and Atlas, 2016; Vom Saal, 2016). Because obesity is 70 a global public health challenge and early life exposure to BPA may be obesogenic 71 there is a need to understand the underlying mechanisms of BPA actions. 72 73 Many human epidemiological studies have linked BPA exposure to metabolic 74 defects, such as insulin resistance, diabetes, obesity and metabolic syndrome 75 (Newbold, 2010; Teppala et al., 2012; Wang et al., 2012) . There is suggestive evidence 76 linking developmental BPA exposure with reduced birth weight (Veiga-Lopez et al., 77 2015a), a major risk factor for adult onset cardio-metabolic disorders (Barker, 2005) . The VAT depot is more responsive to the catecholamine-induced lipolysis and less 91 responsive to the antilipolytic effect of insulin and therefore have a higher rate of fatty 92 acid turnover and lipolysis (Engfeldt and Arner, 1988; Ibrahim, 2010) . In contrast, SAT 93 adipocytes are responsive to insulin action and favor uptake and storage of free fatty 94 acids and triglycerides. In addition, these depots also exhibit a distinct pattern of gene 95 expression such as increased expression of proinflammatory cytokines and adipokines 96 such as tumor necrosis factor alpha (TNF), C reactive peptide (CRP) and interleukin 6 97 (IL6) in VAT than SAT (Ibrahim, 2010) . Because of these functional and transcriptional 98 differences, accumulation of VAT is a risk factor for development of cardiometabolic 99 defects (Lemieux and Despres, 1994; Bjorntorp, 2000; Dobbelsteyn et al., 2001) . 100 Therefore, understanding the depot-specific effects of prenatal BPA treatment can aid in 101 delineating the mechanism of development of adipose and metabolic defects, which are 102 poorly understood. Enriched gene set terms were tested using RNA-enrich ( Figure 2B) , leucine rich 277 repeat neuronal 4 (LRRN4) (-10.9 lower log 2 -fold change, adjusted-p=1.3x10 -8 ), HOXA9 278 (10.0 higher log 2 -fold change, adjusted-p=1.2x10 -13 ) and transcription factor 21 (TCF21) 279 (-9.7 lower log 2 -fold change, adjusted-p=3.2x10 -12 ). Compared to VAT, SAT showed 280 upregulation in genes that participate in skeletal system morphogenesis pathways, and 281 downregulation of genes involved in mitochondrial membrane and vasodilation 282 pathways ( Supplemental Table 3 ). A total of 260 pathways had FDR<0.05, with a set 283 of pathways upregulated in SAT were involved in cellular and tissue development, and 284 immune response, while pathways involved in metabolism, mitochondria, homeostasis, 285 transcription, and translation were downregulated in SAT (Figure 1B) . 286 287
Transcriptional Differences Between Control and BPA-Treated Adipose Depots 288
In SAT, after filtering for low normalized mean counts, 16,388 genes remained in 289 analysis. There were 319 genes differentially expressed between control and BPA-290 treated groups at a false discovery rate adjusted p-value < 0.05, 118 genes differentially 291 expressed with an absolute log 2 -fold change magnitude of difference > 1.5, and 108 292 genes met both these conditions (Figure 2A) . Of the genes meeting these statistical 293 and magnitude criteria, 78% (84 genes) had higher expression in BPA-treated group. 294
Ordered by adjusted p-value, the top differentially expressed genes with BPA treatment 295 relative to control treatment include uncharacterized gene (LOC114116052) (-0.006 296 lower log 2 -fold change expression adjusted-p=7.7x10 -9 ), cyclin N-terminal domain 297 containing 2 (CNTD2) (1.9 higher log 2 -fold change expression, adjusted-p=7.7x10 -9 ) 298 (Supplemental Figure 3A) , 5S ribosomal RNA LOC114116728 (2.5 higher log 2 -fold 299 change expression, adjusted-p=5.9x10 -8 ), and LOC114116239 (2.8 higher log 2 -fold 300 change expression, adjusted-p=2.3x10 -7 ) ( (Supplementary Figure 4) . Table 5 ). The number of genes impacted by BPA in VAT was 320 smaller than the effects in SAT, and there was no overlap in FDR significant genes 321 between the two tissue types (Figure 2C) . 322 323 Several up and downregulated pathways in relation to differential gene 324 expression by BPA were identified through RNA-Enrich. In SAT, BPA downregulated 325 several immune cell pathways (e.g. leukocyte activation, inflammatory response, 326 cytokine production) and upregulated RNA processing pathways (RNA splicing, mRNA 327 metabolic process) (Figure 2D ; Supplemental Table 6 ). BPA in VAT was associated 328 with upregulation of chromatin modification pathway and RNA processing pathways, 329 such as mRNA processing (Figure 2D ; Supplemental Table 7 ). Transcriptional 330 regulation and chromatin modification pathways were upregulated in response to BPA 331 in both SAT and VAT (Figure 2D) . Inflammation, immune, angiogenesis/vasculature 332 development, and cellular and tissue development related pathways were 333 downregulated in SAT, with more mixed or smaller impacts in VAT (Figure 2D) . 334
335
The inflammatory response pathway had more genes affected by BPA in SAT 336 than in VAT (Figure 3) Therefore, increased adiposity of VAT depots in particular is a risk factor for the 387 development of metabolic disorders (Wajchenberg, 2000; Bjorndal et al., 2011) . The 388 findings that VAT was characterized by increased expression of the proinflammatory 389 gene EPHX2 and adiposity associated transcription factor CUX1 are consistent with 390 VAT physiology. Increased expression of EPHX2 has also been reported as a feature of 391 porcine VAT (Gondret et al., 2012) . Increases in EPHX2 expression would likely 392 provoke an inflammatory state in VAT as it converts anti-inflammatory arachidonic acid 393 metabolites into inactive diols (Newman et al., 2005) . In other studies, silencing of this 394 gene ameliorates high fat diet induced obesity associated complications in mouse 395 (Bettaieb et al., 2013) . The transcription factor CUX1 is involved in expression of FTO the increase in TF may be indicative of compensatory process in place to overcome the 408 potential proinflammatory state to maintain insulin sensitivity of this depot, a possibility 409 that needs to be tested further. 410
Comparing patterns in gene expression between SAT and VAT, gene set 411 enrichment indicated genes involved in skeletal system morphogenesis were 412 upregulated in SAT. While the reason for this increase is not clear, genes involved in 413 skeletal system development are reportedly downregulated in VAT from diet-induced 414 obese mouse (Choi et al., 2015) . As this mouse model has increased adiposity with 415 reduced insulin sensitivity and dyslipidemia (Luo et al., 2016) , genes involved in skeletal 416 system development may have a role in lowering risk of insulin resistance, consistent 417 with the metabolic role of SAT relative to VAT (McLaughlin et al., 2011) . In contrast, 418 VAT showed increased enrichment of genes involved in toxic/xenobiotic metabolism, 419 mitochondrial membrane and vasodilation. The increase in these genes may be a result 420 of crosstalk between the gut, liver and VAT due to close proximity (Konrad and Wueest, 421 2014 ) and may stem from the fact that both gut and liver form the first line of defenses 422 against xenobiotic and toxic substances (Hanninen et al., 1979) . Likewise, upregulation 423 of genes involved in vasodilation in VAT are consistent with the observation that visceral 424 adiposity is associated with hypertension (Hall et al., 2015) . While further roles of these 425 depot-specific pattern of gene expression needs to be explored, these differences likely 426 contribute to their differing functions in maintaining metabolic homeostasis. (Table 6) The findings from the present study on impact of prenatal BPA exposure on 488 depot-specific transcriptional profile is of clinical and public health significance in view of 489 the fact that pregnant women are ubiquitously exposed to BPA (Woodruff et al., 2011) 490 and BPA has a role in promoting adipogenesis and obesity (Thayer et al., 2012; 491 Lubrano et al., 2013) . Evidence to date point to EDC contribution to the significant 492 increases in incidences of adipose defects associated with conditions such as 493 abdominal obesity (Trasande et al., 2012; Liu et al., 2017) . The finding that prenatal 494 BPA exposure highly upregulates genes associated with adipogenesis and adiposity in 495 VAT raises the possibility that BPA's contribution to promoting obesity may be VAT 496 depot-specific. While it is well accepted that epigenetic reprogramming forms the basis 497 of BPA-associated adult onset diseases, for the most part such evidence in human 498 tissues comes from non-adipose tissues (Doherty et al., 2010) . Evidence from the 499 present study pointing to predominant changes in genes involved in chromatin 500 modification in both VAT and SAT, is in line with epigenetic contributions to adipose 501 defects. However, these gene sets are highly upregulated in the VAT (Supplemental 502 approach. Other limitations include lack of inclusion of interventional studies to 522 overcome the pathology, an aspect to be considered in future investigations. In 523 conclusion, the results from this study show that exposure to prenatal BPA has adipose-524 depot specific impact on genes involved in inflammation, adipogenesis, adipocyte 525 differentiation, and chromatin remodeling and provide mechanistic cues that could be 526 exploited to understand the pathogenesis and in developing therapeutic strategies. 
